00000107959/302020Q3false0.790.790.790.770.770.770.058653313751.500000107952019-10-012020-06-300000010795exch:XNYSus-gaap:CommonStockMember2019-10-012020-06-300000010795exch:XNYSus-gaap:RedeemablePreferredStockMember2019-10-012020-06-300000010795bdx:Notes1.000dueDecember152022Memberexch:XNYS2019-10-012020-06-300000010795exch:XNYSbdx:Notes1.900dueDecember152026Member2019-10-012020-06-300000010795exch:XNYSbdx:Notes1.401dueMay242023Member2019-10-012020-06-300000010795bdx:Notes3.020dueMay242025Memberexch:XNYS2019-10-012020-06-300000010795bdx:Notes0.174dueJune42021Memberexch:XNYS2019-10-012020-06-300000010795exch:XNYSbdx:Notes0.632dueJune42023Member2019-10-012020-06-300000010795exch:XNYSbdx:Notes1.208dueJune42026Member2019-10-012020-06-30xbrli:shares00000107952020-06-30iso4217:USD00000107952019-09-3000000107952020-04-012020-06-3000000107952019-04-012019-06-3000000107952018-10-012019-06-30iso4217:USDxbrli:shares00000107952018-09-3000000107952019-06-300000010795us-gaap:CommonStockMember2019-09-300000010795us-gaap:AdditionalPaidInCapitalMember2019-09-300000010795us-gaap:RetainedEarningsMember2019-09-300000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2019-09-300000010795us-gaap:TreasuryStockMember2019-09-300000010795us-gaap:RetainedEarningsMember2019-10-012019-12-310000010795us-gaap:AdditionalPaidInCapitalMember2019-10-012019-12-310000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2019-10-012019-12-310000010795us-gaap:TreasuryStockMember2019-10-012019-12-310000010795us-gaap:CommonStockMember2019-12-310000010795us-gaap:AdditionalPaidInCapitalMember2019-12-310000010795us-gaap:RetainedEarningsMember2019-12-310000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2019-12-310000010795us-gaap:TreasuryStockMember2019-12-310000010795us-gaap:RetainedEarningsMember2020-01-012020-03-310000010795us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2020-01-012020-03-310000010795us-gaap:TreasuryStockMember2020-01-012020-03-310000010795us-gaap:CommonStockMember2020-03-310000010795us-gaap:AdditionalPaidInCapitalMember2020-03-310000010795us-gaap:RetainedEarningsMember2020-03-310000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2020-03-310000010795us-gaap:TreasuryStockMember2020-03-310000010795us-gaap:RetainedEarningsMember2020-04-012020-06-300000010795us-gaap:CommonStockMember2020-04-012020-06-300000010795us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300000010795us-gaap:TreasuryStockMember2020-04-012020-06-300000010795us-gaap:CommonStockMember2020-06-300000010795us-gaap:AdditionalPaidInCapitalMember2020-06-300000010795us-gaap:RetainedEarningsMember2020-06-300000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2020-06-300000010795us-gaap:TreasuryStockMember2020-06-300000010795us-gaap:CommonStockMember2018-09-300000010795us-gaap:AdditionalPaidInCapitalMember2018-09-300000010795us-gaap:RetainedEarningsMember2018-09-300000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2018-09-300000010795us-gaap:TreasuryStockMember2018-09-300000010795us-gaap:RetainedEarningsMember2018-10-012018-12-310000010795us-gaap:AdditionalPaidInCapitalMember2018-10-012018-12-310000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2018-10-012018-12-310000010795us-gaap:TreasuryStockMember2018-10-012018-12-310000010795us-gaap:CommonStockMember2018-12-310000010795us-gaap:AdditionalPaidInCapitalMember2018-12-310000010795us-gaap:RetainedEarningsMember2018-12-310000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2018-12-310000010795us-gaap:TreasuryStockMember2018-12-310000010795us-gaap:RetainedEarningsMember2019-01-012019-03-310000010795us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-310000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2019-01-012019-03-310000010795us-gaap:TreasuryStockMember2019-01-012019-03-310000010795us-gaap:CommonStockMember2019-03-310000010795us-gaap:AdditionalPaidInCapitalMember2019-03-310000010795us-gaap:RetainedEarningsMember2019-03-310000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2019-03-310000010795us-gaap:TreasuryStockMember2019-03-310000010795us-gaap:RetainedEarningsMember2019-04-012019-06-300000010795us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-300000010795us-gaap:TreasuryStockMember2019-04-012019-06-300000010795us-gaap:CommonStockMember2019-06-300000010795us-gaap:AdditionalPaidInCapitalMember2019-06-300000010795us-gaap:RetainedEarningsMember2019-06-300000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2019-06-300000010795us-gaap:TreasuryStockMember2019-06-300000010795us-gaap:ConvertiblePreferredStockMember2020-05-010000010795us-gaap:CommonStockMember2020-05-010000010795us-gaap:CommonStockMember2020-05-012020-05-310000010795us-gaap:ConvertiblePreferredStockMember2020-05-012020-05-31xbrli:pure0000010795us-gaap:ConvertiblePreferredStockMember2019-10-012020-06-300000010795us-gaap:ConvertiblePreferredStockMember2020-06-300000010795srt:MinimumMember2020-06-300000010795srt:MaximumMember2020-06-300000010795us-gaap:AccumulatedTranslationAdjustmentMember2019-09-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-09-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-09-3000000107952019-10-012019-12-310000010795us-gaap:AccumulatedTranslationAdjustmentMember2019-10-012019-12-310000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-10-012019-12-310000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-10-012019-12-3100000107952019-12-310000010795us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-3100000107952020-01-012020-03-310000010795us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-03-310000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-03-310000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-03-3100000107952020-03-310000010795us-gaap:AccumulatedTranslationAdjustmentMember2020-03-310000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-03-310000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-03-310000010795us-gaap:AccumulatedTranslationAdjustmentMember2020-04-012020-06-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-04-012020-06-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-04-012020-06-300000010795us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-06-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-06-300000010795us-gaap:AccumulatedTranslationAdjustmentMember2018-09-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-09-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-09-3000000107952018-10-012018-12-310000010795us-gaap:AccumulatedTranslationAdjustmentMember2018-10-012018-12-310000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-10-012018-12-310000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-10-012018-12-3100000107952018-12-310000010795us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-12-310000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-12-3100000107952019-01-012019-03-310000010795us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-03-310000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-03-310000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-03-3100000107952019-03-310000010795us-gaap:AccumulatedTranslationAdjustmentMember2019-03-310000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-03-310000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-03-310000010795us-gaap:AccumulatedTranslationAdjustmentMember2019-04-012019-06-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-04-012019-06-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-04-012019-06-300000010795us-gaap:AccumulatedTranslationAdjustmentMember2019-06-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-06-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-06-300000010795us-gaap:ConvertiblePreferredStockMember2020-05-310000010795us-gaap:ConvertiblePreferredStockMember2020-04-012020-06-300000010795us-gaap:ConvertiblePreferredStockMember2019-04-012019-06-300000010795us-gaap:ConvertiblePreferredStockMember2019-10-012020-06-300000010795us-gaap:ConvertiblePreferredStockMember2018-10-012019-06-300000010795bdx:HerniaProductClaimsMember2020-06-300000010795bdx:WomensHealthProductClaimsMember2020-06-300000010795bdx:WomensHealthProductClaimsMember2018-04-012018-04-300000010795bdx:WomensHealthProductClaimsMemberbdx:CompensatoryMember2018-04-012018-04-300000010795bdx:WomensHealthProductClaimsMemberbdx:PunitiveMember2018-04-012018-04-300000010795bdx:FilterProductClaimsMember2020-06-300000010795bdx:FilterProductClaimsMember2019-10-012020-06-300000010795us-gaap:OtherOperatingIncomeExpenseMember2019-01-012019-03-310000010795us-gaap:OtherOperatingIncomeExpenseMember2019-07-012019-09-300000010795bdx:ProductsandorServicesMember2020-07-012020-06-3000000107952020-07-012020-06-300000010795bdx:ConsumablesMember2020-07-012020-06-30bdx:segment0000010795bdx:MedicationDeliverySolutionsMembercountry:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:MedicationDeliverySolutionsMemberbdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:MedicationDeliverySolutionsMemberbdx:MedicalMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:MedicationDeliverySolutionsMembercountry:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:MedicationDeliverySolutionsMemberbdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:MedicationDeliverySolutionsMemberbdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795country:USbdx:MedicalMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:MedicalMemberus-gaap:NonUsMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:MedicalMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795country:USbdx:MedicalMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:MedicalMemberus-gaap:NonUsMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:MedicalMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:DiabetesCareMembercountry:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:DiabetesCareMemberbdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:DiabetesCareMemberbdx:MedicalMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:DiabetesCareMembercountry:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:DiabetesCareMemberbdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:DiabetesCareMemberbdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:PharmaceuticalSystemsMembercountry:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:PharmaceuticalSystemsMemberbdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:PharmaceuticalSystemsMemberbdx:MedicalMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:PharmaceuticalSystemsMembercountry:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:PharmaceuticalSystemsMemberbdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:PharmaceuticalSystemsMemberbdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795country:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:MedicalMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795country:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795country:USbdx:PreanalyticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2020-04-012020-06-300000010795bdx:PreanalyticalSystemsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2020-04-012020-06-300000010795bdx:PreanalyticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2020-04-012020-06-300000010795country:USbdx:PreanalyticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-04-012019-06-300000010795bdx:PreanalyticalSystemsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-04-012019-06-300000010795bdx:PreanalyticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-04-012019-06-300000010795bdx:DiagnosticSystemsMembercountry:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2020-04-012020-06-300000010795bdx:DiagnosticSystemsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2020-04-012020-06-300000010795bdx:DiagnosticSystemsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2020-04-012020-06-300000010795bdx:DiagnosticSystemsMembercountry:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-04-012019-06-300000010795bdx:DiagnosticSystemsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-04-012019-06-300000010795bdx:DiagnosticSystemsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-04-012019-06-300000010795bdx:IntegratedDiagnosticSolutionsMembercountry:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2020-04-012020-06-300000010795bdx:IntegratedDiagnosticSolutionsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2020-04-012020-06-300000010795bdx:IntegratedDiagnosticSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2020-04-012020-06-300000010795bdx:IntegratedDiagnosticSolutionsMembercountry:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-04-012019-06-300000010795bdx:IntegratedDiagnosticSolutionsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-04-012019-06-300000010795bdx:IntegratedDiagnosticSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-04-012019-06-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMemberbdx:BiosciencesMember2020-04-012020-06-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMemberbdx:BiosciencesMember2020-04-012020-06-300000010795us-gaap:OperatingSegmentsMemberbdx:LifeSciencesMemberbdx:BiosciencesMember2020-04-012020-06-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMemberbdx:BiosciencesMember2019-04-012019-06-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMemberbdx:BiosciencesMember2019-04-012019-06-300000010795us-gaap:OperatingSegmentsMemberbdx:LifeSciencesMemberbdx:BiosciencesMember2019-04-012019-06-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2020-04-012020-06-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2020-04-012020-06-300000010795us-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2020-04-012020-06-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-04-012019-06-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-04-012019-06-300000010795us-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-04-012019-06-300000010795bdx:SurgeryMembercountry:USbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:SurgeryMemberbdx:InterventionalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:SurgeryMemberbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:SurgeryMembercountry:USbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:SurgeryMemberbdx:InterventionalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:SurgeryMemberbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795country:USbdx:PeripheralInterventionMemberbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:PeripheralInterventionMemberbdx:InterventionalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:PeripheralInterventionMemberbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795country:USbdx:PeripheralInterventionMemberbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:PeripheralInterventionMemberbdx:InterventionalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:PeripheralInterventionMemberbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795country:USbdx:InterventionalMemberbdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:InterventionalMemberbdx:UrologyandCriticalCareMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:InterventionalMemberbdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795country:USbdx:InterventionalMemberbdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:InterventionalMemberbdx:UrologyandCriticalCareMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:InterventionalMemberbdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795country:USbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:InterventionalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795bdx:InterventionalMemberus-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795country:USbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:InterventionalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795bdx:InterventionalMemberus-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795country:US2020-04-012020-06-300000010795us-gaap:NonUsMember2020-04-012020-06-300000010795country:US2019-04-012019-06-300000010795us-gaap:NonUsMember2019-04-012019-06-300000010795bdx:IVFluidsMembercountry:US2019-04-012019-06-300000010795country:USbdx:InterventionalSpecialtiesBrachytherapyandFeedingProductsMember2019-04-012019-06-300000010795us-gaap:NonUsMemberbdx:InterventionalSpecialtiesBrachytherapyandFeedingProductsMember2019-04-012019-06-300000010795bdx:MedicationDeliverySolutionsMembercountry:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:MedicationDeliverySolutionsMemberbdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:MedicationDeliverySolutionsMemberbdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:MedicationDeliverySolutionsMembercountry:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:MedicationDeliverySolutionsMemberbdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:MedicationDeliverySolutionsMemberbdx:MedicalMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795country:USbdx:MedicalMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:MedicalMemberus-gaap:NonUsMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:MedicalMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795country:USbdx:MedicalMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:MedicalMemberus-gaap:NonUsMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:MedicalMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:DiabetesCareMembercountry:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:DiabetesCareMemberbdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:DiabetesCareMemberbdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:DiabetesCareMembercountry:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:DiabetesCareMemberbdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:DiabetesCareMemberbdx:MedicalMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:PharmaceuticalSystemsMembercountry:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:PharmaceuticalSystemsMemberbdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:PharmaceuticalSystemsMemberbdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:PharmaceuticalSystemsMembercountry:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:PharmaceuticalSystemsMemberbdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:PharmaceuticalSystemsMemberbdx:MedicalMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795country:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:MedicalMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795country:USbdx:MedicalMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:MedicalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:MedicalMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795country:USbdx:PreanalyticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-10-012020-06-300000010795bdx:PreanalyticalSystemsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-10-012020-06-300000010795bdx:PreanalyticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-10-012020-06-300000010795country:USbdx:PreanalyticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2018-10-012019-06-300000010795bdx:PreanalyticalSystemsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2018-10-012019-06-300000010795bdx:PreanalyticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2018-10-012019-06-300000010795bdx:DiagnosticSystemsMembercountry:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-10-012020-06-300000010795bdx:DiagnosticSystemsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-10-012020-06-300000010795bdx:DiagnosticSystemsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-10-012020-06-300000010795bdx:DiagnosticSystemsMembercountry:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2018-10-012019-06-300000010795bdx:DiagnosticSystemsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2018-10-012019-06-300000010795bdx:DiagnosticSystemsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2018-10-012019-06-300000010795bdx:IntegratedDiagnosticSolutionsMembercountry:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-10-012020-06-300000010795bdx:IntegratedDiagnosticSolutionsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-10-012020-06-300000010795bdx:IntegratedDiagnosticSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-10-012020-06-300000010795bdx:IntegratedDiagnosticSolutionsMembercountry:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2018-10-012019-06-300000010795bdx:IntegratedDiagnosticSolutionsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2018-10-012019-06-300000010795bdx:IntegratedDiagnosticSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2018-10-012019-06-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMemberbdx:BiosciencesMember2019-10-012020-06-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMemberbdx:BiosciencesMember2019-10-012020-06-300000010795us-gaap:OperatingSegmentsMemberbdx:LifeSciencesMemberbdx:BiosciencesMember2019-10-012020-06-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMemberbdx:BiosciencesMember2018-10-012019-06-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMemberbdx:BiosciencesMember2018-10-012019-06-300000010795us-gaap:OperatingSegmentsMemberbdx:LifeSciencesMemberbdx:BiosciencesMember2018-10-012019-06-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-10-012020-06-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-10-012020-06-300000010795us-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2019-10-012020-06-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2018-10-012019-06-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2018-10-012019-06-300000010795us-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2018-10-012019-06-300000010795bdx:SurgeryMembercountry:USbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:SurgeryMemberbdx:InterventionalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:SurgeryMemberbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:SurgeryMembercountry:USbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:SurgeryMemberbdx:InterventionalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:SurgeryMemberbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795country:USbdx:PeripheralInterventionMemberbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:PeripheralInterventionMemberbdx:InterventionalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:PeripheralInterventionMemberbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795country:USbdx:PeripheralInterventionMemberbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:PeripheralInterventionMemberbdx:InterventionalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:PeripheralInterventionMemberbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795country:USbdx:InterventionalMemberbdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:InterventionalMemberbdx:UrologyandCriticalCareMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:InterventionalMemberbdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795country:USbdx:InterventionalMemberbdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:InterventionalMemberbdx:UrologyandCriticalCareMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:InterventionalMemberbdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795country:USbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:InterventionalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795bdx:InterventionalMemberus-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795country:USbdx:InterventionalMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:InterventionalMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795bdx:InterventionalMemberus-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795country:US2019-10-012020-06-300000010795us-gaap:NonUsMember2019-10-012020-06-300000010795country:US2018-10-012019-06-300000010795us-gaap:NonUsMember2018-10-012019-06-300000010795bdx:IVFluidsMembercountry:US2018-10-012019-06-300000010795country:USbdx:InterventionalSpecialtiesBrachytherapyandFeedingProductsMember2018-10-012019-06-300000010795us-gaap:NonUsMemberbdx:InterventionalSpecialtiesBrachytherapyandFeedingProductsMember2018-10-012019-06-300000010795us-gaap:OperatingSegmentsMember2020-04-012020-06-300000010795us-gaap:OperatingSegmentsMember2019-04-012019-06-300000010795us-gaap:OperatingSegmentsMember2019-10-012020-06-300000010795us-gaap:OperatingSegmentsMember2018-10-012019-06-300000010795us-gaap:MaterialReconcilingItemsMember2020-04-012020-06-300000010795us-gaap:MaterialReconcilingItemsMember2019-04-012019-06-300000010795us-gaap:MaterialReconcilingItemsMember2019-10-012020-06-300000010795us-gaap:MaterialReconcilingItemsMember2018-10-012019-06-300000010795us-gaap:CorporateNonSegmentMember2020-04-012020-06-300000010795us-gaap:CorporateNonSegmentMember2019-04-012019-06-300000010795us-gaap:CorporateNonSegmentMember2019-10-012020-06-300000010795us-gaap:CorporateNonSegmentMember2018-10-012019-06-300000010795us-gaap:CostOfSalesMember2020-04-012020-06-300000010795us-gaap:CostOfSalesMember2019-10-012020-06-300000010795us-gaap:OtherNonoperatingIncomeExpenseMember2020-04-012020-06-300000010795bdx:LifeSciencesMember2020-01-012020-03-310000010795us-gaap:OtherOperatingIncomeExpenseMember2019-04-012019-06-300000010795bdx:AdvancedBioprocessingMember2018-10-012019-06-300000010795us-gaap:OtherNonoperatingIncomeExpenseMember2019-10-012020-06-300000010795us-gaap:OtherOperatingIncomeExpenseMember2018-10-012019-06-300000010795us-gaap:PensionPlansDefinedBenefitMember2020-04-012020-06-300000010795us-gaap:PensionPlansDefinedBenefitMember2019-04-012019-06-300000010795us-gaap:PensionPlansDefinedBenefitMember2019-10-012020-06-300000010795us-gaap:PensionPlansDefinedBenefitMember2018-10-012019-06-300000010795bdx:CRBardIncMemberus-gaap:EmployeeSeveranceMember2019-09-300000010795bdx:OtherInitiativesMemberus-gaap:EmployeeSeveranceMember2019-09-300000010795bdx:CRBardIncMemberus-gaap:OtherRestructuringMember2019-09-300000010795bdx:OtherInitiativesMemberus-gaap:OtherRestructuringMember2019-09-300000010795bdx:CRBardIncMember2019-09-300000010795bdx:OtherInitiativesMember2019-09-300000010795bdx:CRBardIncMemberus-gaap:EmployeeSeveranceMember2019-10-012020-06-300000010795bdx:OtherInitiativesMemberus-gaap:EmployeeSeveranceMember2019-10-012020-06-300000010795bdx:CRBardIncMemberus-gaap:OtherRestructuringMember2019-10-012020-06-300000010795bdx:OtherInitiativesMemberus-gaap:OtherRestructuringMember2019-10-012020-06-300000010795bdx:CRBardIncMember2019-10-012020-06-300000010795bdx:OtherInitiativesMember2019-10-012020-06-300000010795bdx:CRBardIncMemberus-gaap:EmployeeSeveranceMember2020-06-300000010795bdx:OtherInitiativesMemberus-gaap:EmployeeSeveranceMember2020-06-300000010795bdx:CRBardIncMemberus-gaap:OtherRestructuringMember2020-06-300000010795bdx:OtherInitiativesMemberus-gaap:OtherRestructuringMember2020-06-300000010795bdx:CRBardIncMember2020-06-300000010795bdx:OtherInitiativesMember2020-06-300000010795us-gaap:DevelopedTechnologyRightsMember2020-06-300000010795us-gaap:DevelopedTechnologyRightsMember2019-09-300000010795us-gaap:CustomerRelationshipsMember2020-06-300000010795us-gaap:CustomerRelationshipsMember2019-09-300000010795bdx:ProductRightsMember2020-06-300000010795bdx:ProductRightsMember2019-09-300000010795us-gaap:TrademarksMember2020-06-300000010795us-gaap:TrademarksMember2019-09-300000010795us-gaap:IntellectualPropertyMember2020-06-300000010795us-gaap:IntellectualPropertyMember2019-09-300000010795us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember2020-06-300000010795us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember2019-09-300000010795us-gaap:TrademarksMember2020-06-300000010795us-gaap:TrademarksMember2019-09-300000010795bdx:MedicalMember2019-09-300000010795bdx:LifeSciencesMember2019-09-300000010795bdx:InterventionalMember2019-09-300000010795bdx:MedicalMember2019-10-012020-06-300000010795bdx:LifeSciencesMember2019-10-012020-06-300000010795bdx:InterventionalMember2019-10-012020-06-300000010795bdx:MedicalMember2020-06-300000010795bdx:LifeSciencesMember2020-06-300000010795bdx:InterventionalMember2020-06-300000010795us-gaap:ForeignExchangeContractMember2020-06-300000010795us-gaap:ForeignExchangeContractMember2019-09-300000010795us-gaap:DebtMemberus-gaap:NetInvestmentHedgingMember2020-06-300000010795us-gaap:DebtMemberus-gaap:NetInvestmentHedgingMember2019-09-300000010795us-gaap:CurrencySwapMember2020-06-300000010795us-gaap:CurrencySwapMember2019-09-300000010795bdx:ForeignCurrencyDenominatedDebtMember2020-04-012020-06-300000010795bdx:ForeignCurrencyDenominatedDebtMember2019-04-012019-06-300000010795bdx:ForeignCurrencyDenominatedDebtMember2019-10-012020-06-300000010795bdx:ForeignCurrencyDenominatedDebtMember2018-10-012019-06-300000010795us-gaap:CurrencySwapMember2020-04-012020-06-300000010795us-gaap:CurrencySwapMember2019-04-012019-06-300000010795us-gaap:CurrencySwapMember2019-10-012020-06-300000010795us-gaap:CurrencySwapMember2018-10-012019-06-300000010795us-gaap:ForeignExchangeForwardMember2020-04-012020-06-300000010795us-gaap:ForeignExchangeForwardMember2019-04-012019-06-300000010795us-gaap:ForeignExchangeForwardMember2019-10-012020-06-300000010795us-gaap:ForeignExchangeForwardMember2018-10-012019-06-300000010795us-gaap:FairValueHedgingMemberbdx:FixedToFloatingMember2020-06-300000010795us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2020-06-300000010795us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2019-10-012020-06-300000010795us-gaap:CashFlowHedgingMemberus-gaap:CommodityContractMember2020-06-300000010795us-gaap:FairValueHedgingMemberbdx:FixedToFloatingMember2019-09-300000010795us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2019-09-300000010795srt:MinimumMember2019-10-012020-06-300000010795srt:MaximumMember2019-10-012020-06-300000010795bdx:SurgeryMember2019-04-012019-06-300000010795bdx:TermLoanFacilityMember2019-10-012020-06-300000010795bdx:TermLoanFacilityMember2020-03-310000010795bdx:TermLoanFacilityMember2020-04-012020-06-300000010795us-gaap:RevolvingCreditFacilityMember2020-03-310000010795us-gaap:RevolvingCreditFacilityMember2020-06-300000010795bdx:Notes2823DueMay202030Member2020-06-300000010795bdx:Notes3794DueMay202050Member2020-06-300000010795bdx:Notes2404DueJune52020Member2020-06-300000010795bdx:Notes3250DueNovember122020Member2020-06-300000010795bdx:Notes3250DueNovember122020Member2020-04-012020-06-30

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2020
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission file number 001-4802
Becton, Dickinson and Company
(Exact name of registrant as specified in its charter)
New Jersey 22-0760120
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification No.)
1 Becton Drive,
Franklin Lakes,
New Jersey
07417-1880
(201)847-6800
(Address of principal executive offices) (Zip Code)(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of Each Exchange on Which Registered
Common stock, par value $1.00BDXNew York Stock Exchange
Depositary Shares, each representing a 1/20th interest in a share of 6.00% Mandatory Convertible Preferred Stock, Series BBDXBNew York Stock Exchange
1.000% Notes due December 15, 2022BDX22ANew York Stock Exchange
1.900% Notes due December 15, 2026BDX26New York Stock Exchange
1.401% Notes due May 24, 2023BDX23ANew York Stock Exchange
3.020% Notes due May 24, 2025BDX25New York Stock Exchange
0.174% Notes due June 4, 2021BDX/21New York Stock Exchange
0.632% Notes due June 4, 2023BDX/23ANew York Stock Exchange
1.208% Notes due June 4, 2026BDX/26ANew York Stock Exchange
        Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
        Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No   ☐
        Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer 
  Accelerated filer 
Non-accelerated filer Smaller reporting company 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  ☒
There were 289,868,551 shares of Common Stock, $1.00 par value, outstanding at June 30, 2020.


BECTON, DICKINSON AND COMPANY
FORM 10-Q
For the quarterly period ended June 30, 2020
TABLE OF CONTENTS
  
Page
Number
Part I.FINANCIAL INFORMATION
Item 1.
Item 2.
Item 3.
Item 4.
Part II.
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
2


ITEM 1. FINANCIAL STATEMENTS
BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED BALANCE SHEETS
Millions of dollars
June 30,
2020
September 30,
2019
Assets(Unaudited)
Current Assets:
Cash and equivalents$2,882  $536  
Restricted cash82  54  
Short-term investments22  30  
Trade receivables, net1,993  2,345  
Inventories:
Materials627  544  
Work in process336  318  
Finished products1,983  1,717  
2,945  2,579  
Prepaid expenses and other903  1,119  
Total Current Assets8,827  6,664  
Property, Plant and Equipment11,660  11,128  
Less allowances for depreciation and amortization5,819  5,469  
Property, Plant and Equipment, Net5,841  5,659  
Goodwill23,549  23,376  
Developed Technology, Net10,356  11,054  
Customer Relationships, Net3,186  3,424  
Other Intangibles, Net567  500  
Other Assets1,632  1,088  
Total Assets$53,959  $51,765  
Liabilities and Shareholders’ Equity
Current Liabilities:
Short-term debt$1,630  $1,309  
Payables, accrued expenses and other current liabilities4,437  4,345  
Total Current Liabilities6,067  5,655  
Long-Term Debt17,090  18,081  
Long-Term Employee Benefit Obligations1,297  1,272  
Deferred Income Taxes and Other Liabilities5,483  5,676  
Commitments and Contingencies (See Note 5)
Shareholders’ Equity
Preferred stock2  2  
Common stock365  347  
Capital in excess of par value19,228  16,270  
Retained earnings12,916  12,913  
Deferred compensation23  23  
Common stock in treasury - at cost(6,145) (6,190) 
Accumulated other comprehensive loss(2,367) (2,283) 
Total Shareholders’ Equity24,022  21,081  
Total Liabilities and Shareholders’ Equity$53,959  $51,765  
Amounts may not add due to rounding.
See notes to condensed consolidated financial statements
3


BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
Millions of dollars, except per share data
(Unaudited)
 Three Months Ended
June 30,
Nine Months Ended
June 30,
 2020201920202019
Revenues$3,855  $4,350  $12,333  $12,706  
Cost of products sold2,195  2,276  6,962  6,684  
Selling and administrative expense980  1,076  3,126  3,238  
Research and development expense262  282  797  792  
Acquisitions and other restructurings74  90  235  281  
Other operating (income) expense, net(15)   (15) 61  
Total Operating Costs and Expenses3,497  3,725  11,104  11,056  
Operating Income358  626  1,229  1,649  
Interest expense(135) (156) (405) (498) 
Interest income2  2  5  8  
Other income (expense), net23  (11) 12  19  
Income Before Income Taxes248  460  842  1,178  
Income tax (benefit) provision(38) 9  96  107  
Net Income286  451  746  1,071  
Preferred stock dividends(9) (38) (84) (114) 
Net income applicable to common shareholders$277  $413  $662  $957  
Basic Earnings per Share$0.98  $1.53  $2.41  $3.55  
Diluted Earnings per Share$0.97  $1.51  $2.38  $3.49  
Dividends per Common Share$0.79  $0.77  $2.37  $2.31  
Amounts may not add due to rounding.
See notes to condensed consolidated financial statements
4


BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Millions of dollars
(Unaudited)
 Three Months Ended
June 30,
Nine Months Ended
June 30,
 2020201920202019
Net Income$286  $451  $746  $1,071  
Other Comprehensive Income (Loss), Net of Tax
Foreign currency translation adjustments34  (68) (66) (27) 
Defined benefit pension and postretirement plans17  12  50  40  
Cash flow hedges2  (3) (68) (2) 
Other Comprehensive Income (Loss), Net of Tax53  (58) (83) 12  
Comprehensive Income$338  $393  $663  $1,082  
Amounts may not add due to rounding.
See notes to condensed consolidated financial statements
5


BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Millions of dollars
(Unaudited)
 Nine Months Ended
June 30,
 20202019
Operating Activities
Net income $746  $1,071  
Adjustments to net income to derive net cash provided by operating activities:
Depreciation and amortization1,601  1,700  
Share-based compensation193  208  
Deferred income taxes(203) (172) 
Change in operating assets and liabilities(248) (661) 
Pension obligation77  (150) 
Gain on sale of business  (336) 
Product liability-related charge  331  
Other, net(107) (32) 
Net Cash Provided by Operating Activities2,058  1,959  
Investing Activities
Capital expenditures(597) (599) 
Acquisitions of businesses, net of cash acquired(139)   
Proceeds from divestitures, net  477  
Other, net(169) (178) 
Net Cash Used for Investing Activities(905) (300) 
Financing Activities
Change in credit facility borrowings(485) 300  
Proceeds from long-term debt and term loans3,389  2,224  
Payments of debt and term loans(3,711) (3,882) 
Proceeds from issuance of equity securities2,917    
Dividends paid(773) (737) 
Other, net(106) (204) 
Net Cash Provided by (Used for) Financing Activities1,230  (2,300) 
Effect of exchange rate changes on cash and equivalents and restricted cash(9) (1) 
Net increase (decrease) in cash and equivalents and restricted cash2,374  (642) 
Opening Cash and Equivalents and Restricted Cash590  1,236  
Closing Cash and Equivalents and Restricted Cash$2,964  $594  
Amounts may not add due to rounding.
See notes to condensed consolidated financial statements
6


BECTON, DICKINSON AND COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2020
Note 1 – Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, in the opinion of the management of Becton, Dickinson and Company (the "Company" or "BD"), include all adjustments which are of a normal recurring nature, necessary for a fair presentation of the financial position and the results of operations and cash flows for the periods presented. However, the financial statements do not include all information and accompanying notes required for a presentation in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s 2019 Annual Report on Form 10-K. Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.
Note 2 – Accounting Changes
New Accounting Principles Adopted
In February 2016, the Financial Accounting Standards Board ("FASB") issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet, as well as requires expanded disclosures regarding leasing arrangements. The Company adopted this standard on October 1, 2019 and elected certain practical expedients permitted under the transition guidance, including a transition method which allows application of the new standard at its adoption date, rather than at the earliest comparative period presented in the financial statements. The Company also elected not to perform any reassessments relative to its expired and existing leases upon its adoption of the new requirements. The Company's adoption of this standard did not materially impact its condensed consolidated financial statements. Additional disclosures regarding the Company’s lease arrangements are provided in Note 15.
In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The Company early adopted this standard as of April 1, 2020 on a prospective basis. The adoption of this standard did not materially impact the Company's condensed consolidated financial statements.
New Accounting Principle Not Yet Adopted
In June 2016, the FASB issued a new accounting standard which requires earlier recognition of credit losses on loans and other financial instruments held by entities, including trade receivables. The new standard requires entities to measure all expected credit losses for financial assets held at each reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption on October 1, 2020.
7


Note 3 – Shareholders' Equity
Changes in certain components of shareholders' equity for the first three quarters of fiscal years 2020 and 2019 were as follows:
 Common
Stock  Issued
at Par Value
Capital in
Excess of
Par Value
Retained
Earnings
Deferred
Compensation
Treasury Stock
(Millions of dollars)Shares (in
thousands)
Amount
Balance at September 30, 2019$347  $16,270  $12,913  $23  (76,260) $(6,190) 
Net income—  —  278  —  —  —  
Common dividends ($0.79 per share)—  —  (215) —  —  —  
Preferred dividends—  —  (38) —  —  —  
Common stock issued for share-based compensation and other plans, net—  (32) —  1  758  (38) 
Share-based compensation—  82  —  —  —  —  
Common stock held in trusts, net (a)—  —  —  —  (12) —  
Balance at December 31, 2019$347  $16,320  $12,938  $24  (75,514) $(6,228) 
Net income—  —  183  —  —  —  
Common dividends ($0.79 per share)—  —  (215) —  —  —  
Preferred dividends—  —  (38) —  —  —  
Common stock issued for share-based compensation and other plans, net—  (91) —  (1) 573  70  
Share-based compensation—  58  —  —  —  —  
Common stock held in trusts, net (a)—  —  —  —  30  —  
Balance at March 31, 2020$347  $16,288  $12,868  $23  (74,911) $(6,158) 
Net income—  —  286  —  —  —  
Common dividends ($0.79 per share)—  —  (229) —  —  —  
Preferred dividends—  —  (9) —  —  —  
Common stock issued for:
Preferred shares converted to common shares12  (9) —  —  —  —  
Public equity offerings6  2,909  —  —  —  —  
Share-based compensation and other plans, net—  (12) —  —  127  13  
Share-based compensation—  52  —  —  —  —  
Common stock held in trusts, net (a)—  —  —  —  13  —  
Balance at June 30, 2020$365  $19,228  $12,916  $23  (74,771) $(6,145) 
8


 Common
Stock  Issued
at Par Value
Capital in
Excess of
Par Value
Retained
Earnings
Deferred
Compensation
Treasury Stock
(Millions of dollars)Shares (in
thousands)
Amount
Balance at September 30, 2018$347  $16,179  $12,596  $22  (78,463) $(6,243) 
Net income—  —  599  —  —  —  
Common dividends ($0.77 per share)—  —  (207) —  —  —  
Preferred dividends—  —  (38) —  —  —  
Common stock issued for share-based compensation and other plans, net—  (97) —  2  851  9  
Share-based compensation—  92  —  —  —  —  
Common stock held in trusts, net (a)—  —  —  —  (12) —  
Effect of change in accounting principles—  —  68  —  —  —  
Balance at December 31, 2018$347  $16,174  $13,018  $24  (77,624) $(6,235) 
Net income—  —  20  —  —  —  
Common dividends ($0.77 per share)—  —  (208) —  —  —  
Preferred dividends—  —  (38) —  —  —  
Common stock issued for share-based compensation and other plans, net—  (57) (1) (1) 618  42  
Share-based compensation—  60  —  —  —  —  
Common stock held in trusts, net (a)—  —  —  —  50  —  
Balance at March 31, 2019$347  $16,177  $12,792  $23  (76,955) $(6,192) 
Net income—  —  451  —  —  —  
Common dividends ($0.77 per share)—  —  (208) —  —  —  
Preferred dividends—  —  (38) —  —  —  
Common stock issued for share-based compensation and other plans, net—  (6) —  —  219  (8) 
Share-based compensation—  56  —  —  —  —  
Common stock held in trusts, net (a)—  —  —  —  4  —  
Balance at June 30, 2019$347  $16,227  $12,997  $23  (76,733) $(6,201) 
(a)Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.
Common and Preferred Stock Conversions and Offerings
In accordance with their terms, the Company's 2.475 million mandatory convertible preferred shares that were issued in May 2017 in connection with the Company's acquisition of C.R. Bard, Inc. ("Bard") were converted into 11.703 million shares of BD common stock on the mandatory conversion date of May 1, 2020.
Also, in May 2020, the Company completed registered public offerings of equity securities including:
6.250 million shares of the Company's common stock for net proceeds of $1.459 billion (gross proceeds of $1.500 billion).
1.500 million shares of the Company's mandatory convertible preferred stock (ownership is held in the form of depositary shares, each representing a 1/20th interest in a share of preferred stock) for net proceeds of $1.459 billion (gross proceeds of $1.500 billion). If and when declared, dividends on the mandatory convertible preferred stock will be payable on a cumulative basis at an annual rate of 6.00% on the liquidation preference of $1,000 per preferred share ($50 per depositary share). The shares of preferred stock are convertible to a minimum of 5.2 million and up to a maximum of 6.2 million shares of Company common stock at an exchange ratio, based on the market price of the Company’s common stock at the date of conversion, and no later than the mandatory conversion date of June 1, 2023.
The Company will use the net proceeds from these offerings for general corporate purposes, which may include funding for the Company's growth strategy through organic investments and acquisitions, working capital, capital expenditures and repayment of outstanding indebtedness.
9


The components and changes of Accumulated other comprehensive income (loss) for the first three quarters of fiscal years 2020 and 2019 were as follows:
(Millions of dollars)TotalForeign Currency
Translation
Benefit Plans
Cash Flow Hedges
Balance at September 30, 2019$(2,283) $(1,256) $(1,005) $(23)